Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Absolute and Relative Effectiveness of Cell Culture-Based and Egg-Based Quadrivalent Inactivated Influenza (Flu) Vaccine Products From the 2014-2015 to 2018-2019 Seasons, US Flu VE Network.
Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundEstimates of the annual effectiveness of influenza vaccination combine multiple vaccine types. Reports of brand/product-specific vaccine effectiveness (VE) of egg-based and cell culture-based quadrivalent inactivated influenza vaccines (IIV4 and ccIIV4, respectively) are limited.
methodsUsing an observational test-negative study design, we compared the effectiveness of selected IIV4 and ccIIV4 products among outpatients enrolled in the US Influenza Vaccine Effectiveness (Flu VE) Network from 2014-2015 to 2018-2019. We used multivariable logistic regression to estimate the product-specific and age group-specific absolute VE and relative VE (rVE) of recommended, age-appropriate vaccines against symptomatic laboratory-confirmed outpatient influenza. The rVE of ccIIV4 versus IIV4 products was estimated during 2 seasons from 2017-2019 among participants aged ≥4 years.
resultsPooling data from 5 influenza seasons when 18% and 15% of vaccinated patients had received Fluarix Quadrivalent or Fluzone Quadrivalent IIV4, respectively, the VE against influenza was 32% for Fluarix and 37% for Fluzone. Pooling 2 seasons when 11% and 28% of vaccinated patients had received ccIIV4 (Flucelvax Quadrivalent) and IIV4 (FluLaval Quadrivalent), respectively, the VE against influenza for each product was 30%. The absolute VE compared with unvaccinated patients was lowest against influenza A(H3N2) compared with that against A(H1N1)pdm09 and each B lineage; VE point estimates were lowest among patients aged ≥50 years compared with 2 younger age groups. The rVE estimates were not statistically significant, indicating similar protection across vaccine products.
conclusionsComparisons of influenza vaccine products over multiple seasons showed benefit of both IIV4 and ccIIV4 against symptomatic laboratory-confirmed outpatient influenza, with similar absolute and relative levels of protection provided by each product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.